Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Michèle Cavo et al.|New England Journal of Medicine|2023Cited by 695
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Doris K. Hansen, Surbhi Sidana et al.|Journal of Hematology & Oncology|2024Cited by 46